Firazyr

Firazyr is a prescription medication that contains the active ingredient icatibant at a strength of 30 mg/0.3 mL in a solution for subcutaneous injection. It is classified as a bradykinin B2 receptor antagonist and is marketed in the European Union for the treatment of acute hereditary angioedema attacks. The drug works by competitively blocking bradykinin‑mediated vascular effects. It is administered by a single self‑injectable dose and is stored at room temperature.

Firazyr is indicated for the management of acute episodes of hereditary angioedema (HAE) in patients with type I or type II deficiency.

- Treatment of sudden swelling of the face, lips, tongue, or extremities associated with HAE. - Relief of abdominal pain and gastrointestinal edema caused by HAE attacks. - Use in patients who have previously responded to icatibant therapy. - Administration when other on‑demand therapies are unavailable or contraindicated. - Option for self‑administration at home under medical supervision.

The safety profile of Firazyr includes both frequently observed and less common adverse events.

Common: - Injection site pain, redness, or swelling. - Transient headache. - Nausea or mild gastrointestinal discomfort. - Flushing of the skin.

Serious: - Severe allergic reaction (anaphylaxis) with difficulty breathing. - Hypotension or sudden drop in blood pressure. - Angioedema at a site other than the HAE episode. - Persistent or worsening abdominal pain.

Before using Firazyr, healthcare providers should consider several precautionary measures to ensure safe administration.

- Assess patient history for hypersensitivity to icatibant or any formulation components. - Use caution in patients with cardiovascular disease or low blood pressure. - Monitor for signs of anaphylaxis after injection, especially during the first dose. - Do not administer if the patient is currently experiencing a severe allergic reaction. - Evaluate pregnancy status; safety data are limited, and the drug is classified as pregnancy category unknown. - Adjust dosing only under specialist guidance; off‑label use is not recommended.

Firazyr may interact with other medicines, and certain combinations should be avoided or used with clinical monitoring.

Avoid: - Concurrent use of ACE inhibitors or angiotensin receptor blockers that can increase bradykinin levels. - Simultaneous administration of other bradykinin B2 receptor antagonists.

Use with caution: - Concomitant use of diuretics that may affect blood pressure. - Co‑administration with other biologic agents for HAE, such as C1‑esterase inhibitor concentrates. - Use alongside medications that cause hypotension, requiring blood pressure monitoring.